Panghal, R. S.Shit, Shiba Prasad2017-08-162017-08-162008http://krishikosh.egranth.ac.in/handle/1/5810028670The oral maximum tolerated dose (MTD) of indoxacarb formulation (Kingdoxa) after was 500 and 600 mg/kg in mice and rats, respectively. The major gross observable symptoms induced by indoxacarb in mice and rats were motor incoordination, vigorous rolling, salivation, restlessness, head tilt, intermittent clonic convulsions, depression, open mouth breathing and death. Indoxacarb treated rats and mice showed decrease in body weight gain and decrease in haemoglobin content, leukocyte counts and erythrocyte counts, which indicated that it has adverse effects on erythropoietic system. Indoxacarb decreased spontaneous motor activity (SMA) and force locomotor activity (FLA) in mice at both the dose levels (100 and 200 mg/kg) in mice. The effect of amphetamine induced increased locomotor activity was antagonized by indoxacarb in mice. The compound produces no analgesic and tranquillizing activity in mice and rats respectively. Indoxacarb produced some protection against supramaximal electroshock induced seizures and potentiated metrazole induced convulsions and strychnine induced convulsions in mice. The body weight gain was not affected significantly in rats in 14 and 28 days studies at the dose levels of 12 and 24 mg/kg. Indoxacarb was found to decrease in haemoglobin concentration, erythrocyte counts and leukocyte counts significantly at both the dose levels in 28 days study. Slight congested lungs and liver and increased spleen size were observed. The plasma glucose level was increased nonsignificantly at higher dose level. There was significant increase in plasma creatinine level at higher dose in 28 days study. Indoxacarb did not produce any effect on plasma GOT but caused significant increase in plasma GPT levels in rats at both the dose levels in 28 days study. These studies indicated that indoxacarb was moderately toxic to the adult male rats and mice.enThesis